Floatz logo

Istisociclib

Platinum Resistant High Grade Serous Ovarian Cancer

Kronos BioSmall moleculePhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Platinum Resistant High Grade Serous Ovarian Cancer cohort.

Asset / SponsorPhaseRating
Carboplatin
National Cancer Institute (NCI)
Phase 2BB
Metformin
University of Chicago
Phase 2BB
FILGRASTIM
University of Washington
Phase 2B
Paclitaxel Lipid Suspension
Jina Pharmaceuticals Inc.
Phase 3B
Cyclophosphamide
National Cancer Institute (NCI)
Phase 2B

View all 28 →

Same molecule, other indications

Istisociclib is also rated in:

Refractory Solid TumorsDormant
CC
Indicative ·
47 / 100
View asset →
non-Hodgkin lymphomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →